CrystalGenomics Receives Orphan Drug Designation from the US FDA for CG-745 in Pancreatic Cancer
CrystalGenomics, Inc. (KOSDAQ: 083790) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CG-745, a clinical stage histone deacetylase (HDAC) inhibitor being developed for several hematologic malignancies and solid tumors, for the treatment of... - August 30, 2019
CrystalGenomics Signs Export Agreement with PharmArtis for Acelex in Russia
CrystalGenomics, Inc. announced today that they have signed an Export Agreement with PharmArtis International for the commercialization of Acelex® (polmacoxib) in Russia. Based on the terms of the agreement, CrystalGenomics will supply finished product of Acelex to PharmArtis and PharmArtis... - November 24, 2018
CrystalGenomics Signs Export Agreement with Apsen Farmacêutica for Acelex in Brazil
CrystalGenomics, Inc. announced today that they have signed an Export Agreement with Apsen Farmacêutica for the commercialization of Acelex® (polmacoxib) in Brazil. Under the terms of the agreement, Apsen will secure exclusive rights for the Brazilian market to sell and market Acelex... - September 05, 2018
CrystalGenomics and Standigm, Agree to Collaborate on Utilizing Artificial Intelligence and Structure-Based Drug Design Technologies in Drug R&D
CrystalGenomics, Inc. (KOSDAQ: 083790) and Standigm, Inc., today announced the collaborative partnership to apply Artificial Intelligence (AI) to the research and development of novel drugs. Under the agreement, both parties plan to work together by combining the power of Standigm’s AI... - June 01, 2017
Polmacoxib Demonstrates Prevention and Treatment Effects in Colorectal Cancer
CrystalGenomics, Inc., a clinical stage biopharmaceutical company headquartered in Korea, has reported a positive outcome from an investigational preclinical research conducted, in part, at the University of Texas MD Anderson Cancer Center by Dr. Raymond N. DuBois’ laboratory where the... - August 15, 2014
CrystalGenomics Receives KRW 13 Billion in Strategic Investment from the Global Pharmaceutical Industry Development Fund
CrystalGenomics, Inc., a late clinical stage biopharmaceutical company focused on developing and commercializing novel drugs for therapeutic areas of unmet medical needs, has just announced that it has received KRW 13 billion (USD 12.8 Million) from the Global Pharmaceutical Industry Development... - June 27, 2014
CrystalGenomics Scores KRW 3 Billion in Strategic Equity Investment from KSLSF, a Life Science Fund Backed by the City of Seoul and the Ministry of Knowledge Economy
CrystalGenomics, Inc. (KOSDAQ: CRYSTAL [083790]), a clinical stage biopharmaceutical company headquartered in Korea, has just announced that it has successfully raised KRW 3 Billion (USD 2.6 Million) in a private placement to the Korea Seoul Life Science Fund (KSLSF). This is the third time within... - January 16, 2012
CrystalGenomics to Present at J.P. Morgan Healthcare Conference on January 12
CrystalGenomics, Inc. (KOSDAQ: CRYSTAL (083790)), a clinical stage biopharmaceutical company headquartered in Korea, has just announced that Joong Myung Cho, Ph.D., President & CEO, will present an overview of CrystalGenomics’ business strategy and an update on its development pipeline on... - January 11, 2012